User: Guest  Login
Title:

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.

Document type:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Das Pradhan, Aruna; Glynn, Robert J; Fruchart, Jean-Charles; MacFadyen, Jean G; Zaharris, Elaine S; Everett, Brendan M; Campbell, Stuart E; Oshima, Ryu; Amarenco, Pierre; Blom, Dirk J; Brinton, Eliot A; Eckel, Robert H; Elam, Marshall B; Felicio, João S; Ginsberg, Henry N; Goudev, Assen; Ishibashi, Shun; Joseph, Jacob; Kodama, Tatsuhiko; Koenig, Wolfgang; Leiter, Lawrence A; Lorenzatti, Alberto J; Mankovsky, Boris; Marx, Nikolaus; Nordestgaard, Børge G; Páll, Dénes; Ray, Kausik K; Santos, Raul D...     »
Abstract:
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, reduces triglyceride levels and improves other lipid levels. METHODS: In a multinational, double-blind, randomized, controlled trial, we assigned patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia (triglycerid...     »
Journal title abbreviation:
N Engl J Med
Year:
2022
Journal volume:
387
Journal issue:
21
Pages contribution:
1923-1934
Fulltext / DOI:
doi:10.1056/NEJMoa2210645
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/36342113
Print-ISSN:
0028-4793
TUM Institution:
273; Klinik für Herz- und Kreislauferkrankungen im Erwachsenenalter (DHM) (Prof. Schunkert)
 BibTeX